Dawnrays Pharmaceutical

Dawnrays Pharmaceutical (Holdings) Limited is a prominent Hong Kong-listed pharmaceutical group (HKEX: 2348) established in 1995, with its primary manufacturing and R&D operations based in Suzhou, China. The company specializes in the development, manufacture, and sale of cephalosporin antibiotics and various system-specific medicines, including cardiovascular, anti-viral (Hepatitis B), and anti-allergy drugs. It is recognized as one of the few vertically integrated manufacturers in China for third-generation cephalosporins, utilizing advanced solvent crystallization technology. In recent years, Dawnrays has transitioned from a pure generic manufacturer to a hybrid model focusing on 'first-to-market' generics and improved innovative drugs. The company operates through several subsidiaries, including Suzhou Dawnrays Pharmaceutical and Fujian Dawnrays Pharmaceutical, and maintains a strong market presence with its 'An' series of anti-hypertensive products and 'Rallyado' (Entecavir).